Tirzepatide, a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, has generated interest for addressing metabolic complications in thyroid patients
If youre not seeing the fat loss or muscle gains you expected by week 6, your physician increases the dose or modifies the peptide combination rather than keeping you on a static protocol that isnt working
Some people experience semaglutide related fatigue or semaglutide fatigue, which is distinct from general tiredness
Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ
Semaglutide: Also given as a weekly subcutaneous injection, semaglutides dosage increases monthly as tolerated until a maintenance dose is reached
In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release, which together help lower blood sugar levels